Abstract | PURPOSE: EXPERIMENTAL DESIGN: A 3+3 lead in phase I design confirmed the RP2D allowing activation of the single-arm, phase II trial. Zoledronic acid was administered intravenously on day 1, and dasatinib was given orally once daily for 28 days each cycle as twice daily administration caused dose-limiting toxicity (DLT). Response was assessed every three cycles. N-telopeptide (NTx) was serially measured. RESULTS: A total of 25 patients were enrolled. No DLTs were noted at the RP2D of dasatinib = 100 mg/d. Common adverse events were grade 1-2: rash (9/25, 36%), fatigue (9/25, 36%), pain (9/25, 36%), nausea (6/25, 20%). The objective response rate in bone was 5/22 (23%), all partial responses (PR). The clinical benefit rate [PRs + stable disease (SD) ≥ 6 months] in bone was 8/22 (36%). Median time to treatment failure was 2.70 months [95% confidence interval (CI), 1.84-5.72] in the general cohort, 3.65 months (95% CI, 1.97-7.33) in patients with hormone receptor (HR)-positive breast cancer and 0.70 months (95% CI, 0.30-NA) in those with HR-negative disease. Factors associated with response in bone included lower tumor grade, HR-positive status, and pretreatment high NTx levels. CONCLUSIONS: Combination therapy was well tolerated and produced responses in bone in patients with HR-positive tumors. Clin Cancer Res; 22(23); 5706-12. ©2016 AACR.
|
Authors | Zahi Mitri, Rita Nanda, Kimberly Blackwell, Colleen M Costelloe, Ilona Hood, Caimiao Wei, Abenaa M Brewster, Nuhad K Ibrahim, Kimberly B Koenig, Gabriel N Hortobagyi, Catherine Van Poznak, Mothaffar F Rimawi, Stacy Moulder-Thompson, Translational Breast Cancer Research Consortium |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 22
Issue 23
Pg. 5706-5712
(Dec 01 2016)
ISSN: 1557-3265 [Electronic] United States |
PMID | 27166393
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article)
|
Copyright | ©2016 American Association for Cancer Research. |
Chemical References |
- Bone Density Conservation Agents
- Diphosphonates
- Imidazoles
- Zoledronic Acid
- Receptor, ErbB-2
- src-Family Kinases
- Dasatinib
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bone Density Conservation Agents
(therapeutic use)
- Bone Neoplasms
(drug therapy, metabolism, secondary)
- Breast
(drug effects)
- Breast Neoplasms
(drug therapy, metabolism)
- Dasatinib
(therapeutic use)
- Diphosphonates
(therapeutic use)
- Female
- Humans
- Imidazoles
(therapeutic use)
- Middle Aged
- Receptor, ErbB-2
(metabolism)
- Zoledronic Acid
- src-Family Kinases
(metabolism)
|